Method of producing quinoline derivatives or their salts suitable for pharmaceutical purposes

专利摘要:
The invention relates to new quinoline derivatives of the general Formula I <IMAGE> [wherein X is hydrogen, halogen or C1-7-alkoxy; n is 1, 2 or 3; R<1> is hydrogen and R<2> is hydroxy-C1-7-alkyl or C1-7-alkoxy-C1-7-alkyl or a group of the general Formula IV, <IMAGE> (wherein Z stands for -O-, -S-, -NH- or -N(C1-7-alkyl)-; the dotted lines represent optional bonds; and m is 0 or 1) or R<1> and R<2> together with the adjacent nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group which may optionally contain a further oxygen, nitrogen or sulfur heteroatom and may be optionally substituted] and acid addition salts thereof, exhibit a radiosensitizing effect, make hypoxial cells highly sensitive towards radiation and may be used in radiation therapy.
公开号:SU1398773A3
申请号:SU864027590
申请日:1986-06-04
公开日:1988-05-23
发明作者:Береньи Эдит；Варга Ласло；Паллош Ласло；Петец Луиза；Ладаньи Ласло；Темпе Петер；Хартаи Ева；Ковач Агнеш
申请人:Эгиш Дьедьсердьяр (Инопредприятие)；
IPC主号:

专利说明:

This invention relates to a method for producing new quinoline derivatives of the general formula
1 H2 / Kl

(I)
 where X is hydrogen, GssH-;
R, is hydrogen;
I P 2 hydroxy-lower alkyl, lower apkoxy-lower alkyl
or /} where the stroke
Scientific Research Institutes, if necessary, provide available chemically
: bonds, or R, ti R form
: together with the neighboring atom
nitrogen is six-membered, containing-: if necessary, another
; nitrogen or oxygen atom
unsubstituted or substituted by hydroxy or 2-hydroxyethyl group heterocyclic ring;
or their pharmaceutically acceptable acid butyric acid cyanide salts, which have the ability to increase the sensitivity of cells to radiation, the purpose of the invention is to sequester quinoline derivatives or their acid addition salts, which have the ability to irradiate cells to radiation which is not typical for this range of compounds,
Example 1. Preparation of N- (3-nitro-4-quinolyl) -morpholine-carboxamidine,
A solution of 3.56 g (0.02 mol) of morpholine-carbamidine hemisulphate, 0.02 mol of sodium ethoxide and 25 ml of ethanol is heated to boiling for 1 hour, then the sodium sulfate formed is filtered off. 2.09 g (0.01 mol) of 4-chloro-3-nitro-quinoline is added to the resulting morpholine-carbamidine ethanol solution and the orange-colored suspension is heated in reflux for 5 hours. The resulting product is filtered and washed alternately with water. , chloroform and ethanol and dried.
2.62 g of compound are obtained. Output 87%, so pl. 228-230 ° C (ethanol). Elemental analysis. Vytseleno,%: C 55,81; H 5.04; K 23,23
0
five
0
five
0
,
Q
45 Q
,
Found,%: C 55.73; H 5.08; N 23.19.
The salt of (3-nitro-4-quinolyl) -morpholine-carboxamidine formed with an equivalent amount of glyoxylic acid melts at 144-146 ° C and the melting point of the hydrochloride salt is 252-254 ° C.
Example 2, Production of N- (3-nitro-4-quinolyl) -N-tetrahydrofurfurylguanidine.
A solution of 3.86 g (0.02 mol) of tetrahydrofurfurylguanidine disulfate, 0.02 mol of sodium ethoxide and 25 ml of ethanol is heated for 1 h in reflux. 4, in the resulting suspension containing tetrahydrofurfurylguanidine and sodium sulfate, 16 g (0.02 mol) of 4-chloro-3-nitro-quinoline. The reaction mixture is heated for 1 hour until boiling, then cooled, the expanded crystals are filtered, alternately rinsed with saturated sodium bicarbonate, water, ethanol and chloroform and dried .
4.4 g of compound are obtained, yield 70.5%, m.p. 210-212 ° C.
Elemental analysis.
Calculated,%: C 57.13; H 5.43; N 22.21,
Found,%: C 57.28; H 5.59; N 22.30.
PRI me R s 3-11. According to the method of example 1, the following compounds of general formula (l) are obtained.
N- (3-Nitro-4-quinolyl) -4 (2-hydroxyethyl) piperazinyl-1-carboxamidine. M.p. 232-234 ° C, yield 91%.
Elemental analysis.
Calculated,%: C 55.80; H 5.85; H 24.41. ,
Found,%: C 56.68; H 5.99; N 24.31.
N- (3-Nitro-4-quinolyl) -K-furfurylguanidine, m.p. 210-212 ° C, yield 85%.
Elemental analysis.
Calculated,%: C 57.87; H 4.21; N 22.50.
Found,%: C 57.97; H 4.47; N 22.31.
N- (2-Oxyethyl) -N - (Z-nitro-4-quinolyl) -guanidine, m.p. 228-230 ° C, yield 80%.
Elemental analysis.
Calculated,%: C, 52.36; H 4.76; N, 25.44; Found: C, 52.51; H 4.98; N 25.12,.
N- (2-Methoxyethyl) -N - {Z-nitro-4-quinolyl) -guanidine, m.p. 166-168 ° C, yield 85%.
Elemental analysis.
Calculated,%: C 53.97; H 5.23; N 24.21 Found,%: C 53.79; H 5.45; N 24.30.
N- (3-Nitro-4-quinolsh1) -4-methyl-piperazinyl-1-carboxamidine, mp. 249-250 ° C, yield 85%.
Elemental analysis.
Calculated,%: C 57.31; H 5.77; N ,, 26,74 Found,%: C 57.28; H 5.91; N 26.50.
N- (3-Nitro-4-quinolyl) -piperidine-carboxamidine, m.p. 248-251 ° C, yield 70%.
Elemental analysis.
Calculated,%: C 60.19; H 5.73; N 23.40; Found,%: C 60.32; H 5.96; N 23.26N- (3-Nitro-4-quinolyl) -3-hydroxypiperidine-carboxamidine, m.p. 240-242 With BJIhod 87%.
Elemental analysis.
Calculated,%: C 57.13; H 5.43; N 22.21.
Found,%: C 57.30; H 5.68; N 22.12 ,.
N- (3-Nitro-4-quinolyl) -4-hydroxy-piperidine-carboxam Din., Mp. 232-234 With a yield of 88%.
Elemental analysis.
Calculated,%: C 57.13; H 5.43; N 22.21.
Found,%: C 57.31; H 5.51; N 22.31
N- (7-Chloro-3-nitro-4-quinolyl) -morpholine-carboxamidine, m.p. 286-288 С
Elemental analysis.
Calculated,%: C 50.08; H 4.20; N 20.86; C1 10.56 Found,%: C 49.92; H 4.27; . N 21.06; C1 10.22.
The compounds of general formula (l) show an increased susceptibility to irradiation and make hypoxial cells as susceptible as possible with respect to therapeutic radiation.
Effective treatment of human malignant tumors is based on surgery, on the use of chemotherapy
five
0
inactivation by ionizing radiation. Thanks to the use of the methods described, either alone or in their combination, significant progress has been made in curing tumors. However, in many cases, the expected result is missing. The reason for the failure can be explained by the fact that the resistance to irradiation of tumor cells is higher than that of normal tissues. Radiologically more effective irradiation of a new species is necessary to eliminate this reasoned difference. The use of high-speed radiations for linear energy transfer (neutrons, protons, mesons, ions, etc.) is limited by technical and financial barriers. The possibility of increasing the therapeutic efficacy would be an increase in the sensitivity of cancer cells and the protection of normal tissues and cells with the help of 5 radioprotectors (radioprotection). For this reason, a large group of so-called electronffin-radiosensitators and within this group derivatives of nitroimidazole are investigated and thus found. Metronidazole (1- (2-hydroxyethyl) -2-methyl-5-nitro-imidazole) and mezonidazole (3-methoxy-1- (2-nitro-1-imidazole-1- IL) -2-propanol). These chemical substances often increase the sensitivity to irradiation of hypoxial cells by acting by increasing the dose. However, in the clinical trials of the described drugs, patients had severe neurotoxic symptoms.
The compounds of general formula (t) do not exhibit the disadvantages described. They have an efficacy of increasing the dose and a dose summing effect along with favorable toxicity. Therefore, they can be used for the combined treatment of human tumors.
The effect of the new compounds in accordance with the invention can be g confirmed by the following experiments.
The toxicity and the modified effect of: the irradiation effect of the compounds of the general formula (l) are compared with the activity of nitroimidazole, mizonidazole. Opre0
five
0
five
0
the action of the compounds of general formula (l) and mzonidazole is performed on an identical test system in a test tube (CHO cells) and at similar conditions (oxygenated and hypoxic environment, o environment (tissue) with 10% FKS ). One of the representatives of the compounds of the formula (l N- (3-nitro-A-quinolyl) morpholine-carb-oxamidine has the same toxicity as L cac and monosonazole. It also shows favorable toxicity in experimental animals (CFLP mouse), as can be seen from the table.
Table 1
Test connection dose
Continued table. 2
Diamidy3,3
Untreated control 3.75-3.8
Table3
 , 0
15
(Z-Nitro-4-hino-1Sh1) -morpholine-carb-examidine
2000
The advantage of the compounds of general formula (l) is to increase the sensitivity to radiation of chemicals, if we compare the effectiveness of exposure by increasing the dose. This can be numerically characterized by the use of moderate lethal doses. |) Pyty is performed on Chinese homa cages. The results are summarized in table. 2
From the data table, 2 it follows that
The experiments carried out in rodents () confirmed that new compounds of the general formula (l) in the body
long after intravenous or oral administration
Compounds of general formula II) possess stronger potency than 40 animals also have the ability
Honest substances. Increase exposure to irradiation. Determine apparent threshold niches. Observed sensitization in the dose (Da). From a biological point of view, this parameter means that the minimum dose required for a substance indicates a slow end-point exposure (killed in a molecule, a strong no cell). Communication with tissue. It is also very likely that the results obtained are given but that the molecule develops a modified table. 3. The effect of irradiation in its non-Table 2 gg variable form.
Favorable results are also obtained in the course of the studies conducted on transplantable thought tumors. After pretreatment with a compound of general formula (l) of relatively low concentration (0.2 mmol) and local irradiation with a dose of 0 Gy, a value of 1.5-2 is obtained for a coefficient of 5
0
five
The data table. 3 confirms that cell death in the case of using the known misonidazole is found only at a dose of over 5 Gy, in contrast, pretreatment with compounds of the general formula (l) and exposure to small doses already causes significant cell destruction.
Gray is the unit of measurement of the absorbed dose of radiation (1 Gy is the dose of radiation when 1 J of energy with a constant intensity is absorbed into 1 kg of mass with the help of ionizing radiation).
The experiments carried out in rodents () confirmed that new compounds of the general formula (l) in the body
long after intravenous or oral administration
niche. Observed sensitization in the substance indicates a slow exchange of substances in the molecule, a strong bond with the tissue. Also very likely to increase sensitivity.
(SER). .

权利要求:
Claims (4)
[1]
Invention Formula
I, Method for preparing quinoline derivatives of general formula (l)
N C-lir
de
X R, R is hydrogen, halogen;
hydrogen;
hydroxy lower alkyl, lower alkoxy lower alkyl
/ g -V 7 where the stroke line- 2o
ABOUT
Scientific research institutes, if necessary, represent the existing chemical bonds or P., and R-sovili
locally with the neighboring nitrogen atom, they form a six-membered one, containing, if necessary, another nitrogen or oxygen atom, an unsubstituted or substituted by an oxy- or 2-hydroxytyl group, a heterocyclic ring-,
or suitable for pharmaceutical purposes acid addition salts, characterized in that.
compound of general formula (I)
where X is hydrogen; Y is halogen,
subjected to interaction with the amidine salt of general formula (III)
1Ш and
HjlI-C-K
2
where R and R are as defined above, in the presence of an alkali metal alcohol at boiling point, and the resulting compound, of the general formula (l), is converted into a salt suitable for pharmaceutical purposes with an acid.
[2]
2, a method according to claim 1, characterized in that the reaction is carried out. d t in an inert organic solvent.,.
[3]
3. The method according to claim 2, o tl and h aa yi and so that alcohol is used as an inert organic solvent.
[4]
4. The method according to p. 3, 10 and with the fact that it uses ethanol.
about tl and h in quality
a-alcohol

类似技术:

---

公开号 | 公开日 | 专利标题

---

KR960007524B1|1996-06-05|Substituted imidazolyl-alkyl-piperazine and diazepine derivatives for treating cerebrovascular disease

---

Howard et al.1977|Hydrophobicity of several rhodium | carboxylates correlated with their biologic activity

---

US4282232A|1981-08-04|Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof

---

US4294822A|1981-10-13|5-Aminoalkyl-4,4,8-trialkylpsoralens

---

US4631289A|1986-12-23|Useful in radiotherapy of chemotherapy 4-aziridino-1-nitroimidazol-1-yl-2,3-butanediols

---

SU1398773A3|1988-05-23|Method of producing quinoline derivatives or their salts suitable for pharmaceutical purposes

---

US3651080A|1972-03-21|Certain substituted 2-alkylmercaptoimidazole derivatives

---

KR100763211B1|2007-10-08|Novel DNA-cleaving antitumor agents

---

JP3253663B2|2002-02-04|Radiosensitizer

---

DE1670497A1|1972-01-27|Process for the preparation of new alkane and aralkane carboxylic acid amidoximes

---

US6686345B2|2004-02-03|DNA-cleaving antitumor agents

---

US4294854A|1981-10-13|Pharmaceutical compositions

---

CS210659B2|1982-01-29|Method of preparation of amidobenzoic acid derivatives

---

AU603380B2|1990-11-15|Compounds useful in the synthesis of 1-aziridinoalkyl nitroimidazoles

---

US6297284B1|2001-10-02|DNA-cleaving antitumor agents

---

EP0316967B1|1992-09-09|Fluorine-containing nitroimidazole derivatives and radiosensitizer comprising the same

---

SK695188A3|1996-02-07|Enolether amide 1,1-dioxo-6-chloro-4-hydroxy-2-methyl-n-|-2h-thieno |-1,2-thiazine-3-carboxylic acid, method of its production and pharmaceutical agent

---

RU2032660C1|1995-04-10|Method for preparing complexes on the base of acyclic amines having radioprotector properties

---

US3658991A|1972-04-25|Anti-inflammatory methods using derivatives of 2-mercaptoimidazoles

---

JP2564756B2|1996-12-18|Nitrotriazole compound

---

US4619927A|1986-10-28|Novel nitropyrazinyl- and nitropyridinyl- substituted piperazin-3-one and hexahydro-1H-1,4-diazepin-5-one compounds useful as adjuncts to radiation therapy

---

US4649138A|1987-03-10|Pharmaceutical compositions

---

Glen et al.1939|112. The preparation and therapeutic properties of certain 4-substituted quinoline derivatives

---

TH4209B|1994-12-21|Methods for preparing new quinoline derivatives

同族专利:

---

公开号 | 公开日

---

ATA149286A|1990-09-15|

---

AT392469B|1991-04-10|

---

BE904864A|1986-12-03|

---

CH668069A5|1988-11-30|

---

AU588883B2|1989-09-28|

---

FR2582835A1|1986-12-05|

---

JPS6248668A|1987-03-03|

---

IL79024D0|1986-09-30|

---

CS257793B2|1988-06-15|

---

DK262186D0|1986-06-04|

---

PH24135A|1990-03-05|

---

DK162841C|1992-05-04|

---

FR2582835B1|1989-01-06|

---

FI862381A0|1986-06-04|

---

GB8613530D0|1986-07-09|

---

PT82712A|1986-07-01|

---

IT1204377B|1989-03-01|

---

PT82712B|1988-04-21|

---

HU195487B|1988-05-30|

---

CA1266650A|1990-03-13|

---

ES8707231A1|1987-07-16|

---

SE466308B|1992-01-27|

---

DE3618724A1|1987-01-08|

---

DK162841B|1991-12-16|

---

CN86103688A|1987-02-11|

---

NO862230L|1986-12-05|

---

GB2176185B|1988-09-28|

---

GB2176185A|1986-12-17|

---

IT8620667D0|1986-06-04|

---

FI862381A|1986-12-05|

---

DE3618724C2|1994-06-16|

---

ES555708A0|1987-07-16|

---

SE8602524L|1986-12-05|

---

JPH0515705B2|1993-03-02|

---

NO165635B|1990-12-03|

---

PL146498B1|1989-02-28|

---

FI82451C|1991-03-11|

---

DK262186A|1986-12-05|

---

NL8601434A|1987-01-02|

---

KR930006775B1|1993-07-23|

---

DD247448A5|1987-07-08|

---

SE8602524D0|1986-06-04|

---

GR861452B|1986-10-03|

---

KR870000324A|1987-02-17|

---

NO165635C|1991-03-13|

---

FI82451B|1990-11-30|

---

US4652562A|1987-03-24|

---

AU5834486A|1986-12-11|

---

NO862230D0|1986-06-04|

---

CN1012957B|1991-06-26|

---

HUT41008A|1987-03-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

HU165520B|1972-05-05|1974-09-28|

---

IE47458B1|1977-11-07|1984-03-21|Leo Pharm Prod Ltd|Quinolylguanidine derivatives|US20090117199A1|1998-08-06|2009-05-07|Scott Timothy C|Method of treatment of cancer|

---

US8557298B2|1998-08-06|2013-10-15|Provectus Pharmatech, Inc.|Medicaments for chemotherapeutic treatment of disease|

---

US8974363B2|1997-12-11|2015-03-10|Provectus Pharmatech, Inc.|Topical medicaments and methods for photodynamic treatment of disease|

---

US20020001567A1|1998-12-21|2002-01-03|Photogen, Inc.|Intracorporeal medicaments for high energy phototherapeutic treatment of disease|

---

US7384623B1|1998-12-21|2008-06-10|Provectus Pharmatech, Inc.|High energy phototherapeutic agents|

---

US8470296B2|1998-12-21|2013-06-25|Provectus Pharmatech, Inc.|Intracorporeal medicaments for high energy phototherapeutic treatment of disease|

---

US6331286B1|1998-12-21|2001-12-18|Photogen, Inc.|Methods for high energy phototherapeutics|

---

EP1719770A3|2000-09-21|2008-03-05|Smithkline Beecham Plc|Quinoline derivatives as antibacterials|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

HU852193A|HU195487B|1985-06-04|1985-06-04|Process for producing quinoline derivatives|

---